New gene therapy for ALS enters first human safety trial
Disease control
Recruiting now
This early-stage study tests a single dose of a gene therapy called CTx1000 in 15 people with ALS. The main goal is to see if it is safe and tolerable. Participants must have had ALS for 2 years or less and be on stable standard medications. This is not a cure; it aims to control…
Phase: PHASE1 • Sponsor: Celosia Therapeutics Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC